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Abstract
Background Multiple clinical, demographic, and genetic
factors affect the pharmacokinetics of tacrolimus in chil-
dren, yet in daily practice, a uniform body-weight based
starting dose is used. It can take weeks to reach the target
tacrolimus pre-dose concentration.
Objectives The objectives of this study were to determine
the pharmacokinetics of tacrolimus immediately after
kidney transplantation and to find relevant parameters for
dose individualization using a population pharmacokinetic
analysis.
Methods A total of 722 blood samples were collected from
46 children treated with tacrolimus over the first 6 weeks
after renal transplantation. Non-linear mixed-effects mod-
eling (NONMEM) was used to develop a population
pharmacokinetic model and perform a covariate analysis.
Simulations were performed to determine the optimal
starting dose and to develop dosing guidelines.
Results The data were accurately described by a two-
compartment model with allometric scaling for body-
weight. Mean tacrolimus apparent clearance was 50.5 L/h,
with an inter-patient variability of 25%. Higher body-
weight, lower estimated glomerular filtration rate, and
higher hematocrit levels resulted in lower total tacrolimus
clearance. Cytochrome P450 3A5 expressers and recipients
who received a kidney from a deceased donor had a sig-
nificantly higher tacrolimus clearance. The model was
successfully externally validated. In total, these covariates
explained 41% of the variability in clearance. From the
significant covariates, the cytochrome P450 3A5 genotype,
bodyweight, and donor type were useful to adjust the
starting dose to reach the target pre-dose concentration.
Dosing guidelines range from 0.27 to 1.33 mg/kg/day.
Conclusion During the first 6 weeks after transplantation,
the tacrolimus weight-normalized starting dose should be
higher in pediatric kidney transplant recipients with a lower
bodyweight, those who express the cytochrome P450 3A5
genotype, and those who receive a kidney from a deceased
donor.
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Key Points
In the first 6 weeks post-transplantation bodyweight,
the cytochrome P450 3A5 genotype, donor type
(deceased vs. living), estimated glomerular filtration
rate, and hematocrit significantly influence the
clearance of tacrolimus in children receiving a
kidney transplant
The tacrolimus weight-normalized starting dose in
pediatric kidney transplant recipients should be
higher in children with a lower bodyweight, those
who express the cytochrome P450 3A5 genotype,
and in patients who receive a kidney from a deceased
donor
1 Introduction
The use of tacrolimus-based immunosuppressive therapy
following pediatric renal transplantation has drastically
improved patient and graft survival. There still is, however,
a long way to go regarding the reduction in tacrolimus
treatment-related co-morbidities [1, 2]. Adverse events
associated with the use of tacrolimus include nephrotoxi-
city, neurotoxicity, alopecia, gastrointestinal disturbances,
hypertension, and post-transplantation diabetes mellitus
[3–5]. These side effects contribute to patient non-adher-
ence, limited long-term kidney allograft survival, and high
cardiovascular morbidity and mortality of transplant
recipients [6, 7]. High tacrolimus concentrations are asso-
ciated with toxicity and lower concentrations seem to be
related to an increased risk of acute rejection episodes
[8, 9]. Glucocorticoid-sparing protocols are becoming more
common, making it even more crucial to reach the tacro-
limus target concentration as soon as possible to reduce the
risk of acute rejection [8].
Tacrolimus is a critical dose drug with a narrow thera-
peutic index for which therapeutic drug monitoring (TDM)
is routinely performed. Multiple factors, including body-
weight [10, 11], age [12, 13], drug interactions [14],
hematocrit [10, 15], ethnicity [16], treatment with gluco-
corticoids [17], and cytochrome P450 (CYP) 3A genotype
[10] affect the pharmacokinetics of tacrolimus. This has
been extensively investigated in adults; however, data in
children are limited. Children aged younger than 5 years
appear to need higher weight-normalized doses of tacroli-
mus than older children to reach the target range [12]. The
reason for this age-related increased clearance (CL) is
unknown. It has been demonstrated that CYP3A5 expres-
sers (those with the CYP3A5*1/1 or CYP3A5*1/*3
genotype) require at least a 1.5-fold higher tacrolimus dose
compared with CYP3A5 non-expressers (CYP3A5*3/*3
genotype) [10, 12, 18–21]. CYP3A4*22 is associated with
lower tacrolimus dose requirements post-renal transplan-
tation [22–24]. The CYP3A4*1G allele is associated with a
higher tacrolimus dose requirement; however, its contri-
bution to tacrolimus exposure is less than half of that of the
CYP3A5 genotype [25]. This effect is thought to be inde-
pendent of CYP3A5 status [16]. In routine clinical practice,
these factors are not taken into consideration. The starting
dose of tacrolimus is usually based on bodyweight and then
adjusted by means of TDM. Therapeutic drug monitoring
limits the time a patient is exposed to sub- and supra-
therapeutic tacrolimus concentrations, but it can take up to
2 weeks to reach the target exposure range [26].
The use of a population pharmacokinetic model may
help in predicting an individual’s response to tacrolimus
and can be applied before the start of therapy. To date, four
models have been developed for pediatric renal transplant
recipients [20, 27–30]. Of these models, only one was
developed using transplant recipients in the immediate
post-transplant phase and could therefore be used to
determine the starting tacrolimus dose [10]. However, this
model was developed with children treated in nine hospi-
tals with different immunosuppressive regimens, had
sparse tacrolimus sampling, important covariates such as
ethnicity were not included, and the model was not exter-
nally validated.
The aim of the current study was to describe the popu-
lation pharmacokinetics of twice-daily immediate-release
tacrolimus in the first weeks after pediatric renal trans-
plantation and to develop a dosing guideline for the starting
dose. In contrast to previous studies, all children were
treated with the same immunosuppressive regimen, had an
abbreviated time profile measured with additional exten-
sive tacrolimus sampling, important covariates such as
ethnicity and CYP3A5 genotype were included, and the
model was externally validated.
2 Materials and Methods
2.1 Study Design
A retrospective analysis of pediatric transplant recipients
who received a donor kidney between November 2009 and
April 2016 was performed. Clinical and demographic data
were retrieved from the medical records for the first
6 weeks after pediatric renal transplantation. Data were
collected in the pediatric nephrology department at the
Erasmus Medical Center, Sophia Children’s Hospital,
Rotterdam, the Netherlands. Eligible for enrolment were
patients aged younger than 18 years, who received a
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kidney from an ABO compatible living or a deceased
donor, and were treated with tacrolimus as part of their
initial immune suppressive regimen. All clinical values
were collected from 24 h before transplantation until
6 weeks post-transplantation.
External validation of the pharmacokinetic model was
performed on an independent dataset consisting of 23
children who underwent transplantation between March
2012 and July 2015 in the Radboud University Medical
Center, Amalia Children’s Hospital, Nijmegen, The
Netherlands. These children were not included in the initial
model building dataset, and were selected using the same
inclusion criteria.
The study was designed in accordance with the Decla-
ration of Helsinki of 1975. For the model building dataset,
all laboratory analyses were performed for routine clinical
practice. The Ethics Review Board of the Erasmus Medical
Center decided that the rules laid down in the Medical
Research Involving Human Subjects Act do not apply to
this study (Medical Ethical Review Board No. 2017-092).
The extra genotyping was approved by the Ethics Review
Board of the Erasmus Medical Center (No. 2010-219). For
the validation dataset, the Ethics Review Board of the
Radboud University Medical Center approved the geno-
typing for CYP3A5 in leftover material (No. 2014-1282).
The parents or legal caregivers of all participants signed an
informed consent prior to DNA collection.
2.2 Immunosuppression
All patients were treated according to the TWIST protocol
with basiliximab, tacrolimus, mycophenolic acid, and a
5-day course of glucocorticoids [31]. Both the twice-daily
formulations Prograft (Astellas Pharma, Leiden, The
Netherlands) and Modigraf (Astellas Pharma, Leiden,
The Netherlands) granules for suspension were used. An
extemporaneously prepared suspension from the Prograft
capsules in an oral suspending vehicle from our Good
Manufacturing Practice-certified pharmacy was used by
some children. All children received an initial tacrolimus
dose of 0.3 mg/kg/day divided into two doses every 12 h.
The subsequent doses were adjusted using TDM.
In our hospital, it is common to measure the tacrolimus
pre-dose concentration (C0) for the first time after four to
five dosages of tacrolimus, i.e., approximately 3 days after
transplantation. As this is a study with data obtained in
routine clinical practice, not all patients had their first
tacrolimus C0 measurement on day 3. This depended on
multiple factors, including clinical factors (e.g., signs of
tacrolimus toxicity or rejection), as well as logistic factors
(tacrolimus concentrations are not routinely measured
during the weekend in our hospital). In the first 3 weeks
post-transplantation, the target C0 was 10–15 ng/mL, from
then onwards the target C0 was 7–12 ng/mL. Approxi-
mately 2 weeks after transplantation, an abbreviated 4-h
tacrolimus concentration vs. time profile was obtained. For
these profiles, blood samples were taken before tacrolimus
administration, and 10, 30, 90, 120, and 240 min post-
ingestion. The dose of immunosuppression and other co-
medication was recorded in the electronic prescribing
system during the entire study period. Tacrolimus sample
collection times and time of latest ingestion were also
recorded.
The following clinical data were collected retrospec-
tively from medical records: weight, height, time post-
transplant, sex, age, ethnicity, hematocrit, creatinine,
aspartate aminotransferase, albumin, C-reactive protein,
total protein, CYP3A4 genotype, CYP3A5 genotype, co-
medication, glucocorticoid dose, primary diagnosis, pre-
vious transplantations, renal replacement therapy prior to
transplantation (pre-emptive, hemodialysis or peritoneal
dialysis), donor (living or post-mortal), human leukocyte
antigen mismatches. The estimated glomerular filtration
rate (eGFR) was calculated using the adapted Schwartz
formula (K * height (cm)/serum creatinine (lmol/L) with a
K value of 36.5 and the body surface area using the formula
according to Mosteller [32, 33].
2.3 Laboratory Analysis
Genotyping for CYP3A5 and CYP3A4 was performed as
described previously [34]. For CYP3A4, the *1G and *22
polymorphisms were tested, and for CYP3A5 we tested for
the *3 and *7 alleles. Deviations from the Hardy–Weinberg
equilibrium were tested using the Chi squared goodness-of-
fit test. Most tacrolimus concentrations were analyzed in
whole-blood samples using a validated liquid chromatog-
raphy-tandem mass spectrometry (LC–MS/MS) method,
with a lower limit of quantification of 1.0 ng/mL. The
remaining tacrolimus concentrations of the model building
dataset (9%) were measured before the introduction of the
LC–MS/MS method using the immunoassay with a lower
limit of quantification of 1.5 ng/mL. The accuracy of the
quality-control samples was between 85 and 115% and the
intra- and inter-assay imprecision was less than 15% during
the study period. As it is known that there is a difference
between tacrolimus concentrations measured using an LC–
MS/MS and an immunoassay, this was built into the
residual error model.
2.4 Population Pharmacokinetic Modeling
Pharmacokinetic analysis was conducted by non-linear
mixed-effects modeling using NONMEM Version 7.2
(FOCE?I; ICON Development Solutions, Ellicott City,
MD, USA) and PsN Version 4.6.0. Pirana software was
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used as an interface between NONMEM, R (version
3.2.2) and Xpose (version 4).
2.4.1 Base Model Development
Based on visual inspection of the data and a review of the
literature, one- and two-compartment models were con-
sidered to describe the concentration–time data. Typical
values for lag-time, absorption rate constant (ka), volume
of distribution, CL, and inter-compartmental clearance
(Q) were estimated. Bioavailability could not be quantified;
therefore, certain parameters were estimated as ratios:
apparent oral clearance (CL/F), Q/F, and apparent volume
of distribution. Inter-individual variability (IIV) and inter-
occasion variability (IOV) were modeled for each phar-
macokinetic parameter using an exponential model, and
residual variability was incorporated as an additive and
proportional error for each analytical method. Allometric
scaling was used to account for variability in pharma-
cokinetic parameters owing to differences in bodyweight.
Shrinkage was calculated for all model parameters for
which IIV was estimated. A shrinkage value below 20%
was considered acceptable [35]. Model selection was based
on minimum objective function values (OFVs), parameter
precision, error estimates, shrinkage values, and visual
inspection of the goodness-of-fit plots.
2.4.2 Covariate Model Development
Covariates were selected on the basis of their known or
theoretical relationships with tacrolimus pharmacokinetics.
Demographic, clinical, and genetic characteristics were
evaluated as potential model covariates, all selected
covariates are shown in Table 1. Co-medications known to
interact with the tacrolimus concentration were included.
The differences between the capsules and suspension
(Modigraf and the extemporaneously prepared suspen-
sion) were also tested as a covariate.
The relationship between covariates and IIV was first
investigated graphically and covariates with a visually
apparent relationship were singly added to the model. A
univariate analysis was performed to determine if they
improved the model. The forward inclusion-backward
elimination method was used [36]. Covariates that sig-
nificantly improved the model (p\ 0.05) were added to
the full model. A backward elimination process was then
performed with a stricter statistical significance of
p\ 0.001 (OFV[ 10.83). To be accepted in the model,
the covariate also needed to reduce the IIV of the
pharmacokinetic parameter involved. A shark plot was
generated for each covariate for case-deletion
diagnostics.
2.4.3 Model Evaluation
Multiple procedures were used to validate the final model.
First of all, a bootstrap resampling method was applied
[37]. Five hundred bootstrap datasets were generated by
sampling randomly from the original dataset with
replacement. The validity of the model was evaluated by
comparing the median values and their corresponding 95%
confidence intervals of the bootstrap replicates with the
estimates of the original dataset. The model was further
validated using the visual predictive check (VPC) by
simulating 500 datasets [38], and a normalized prediction
distribution errors (NPDE) analysis [39]. To investigate
how the OFV differences between the covariate and base
model is distributed across individuals, a shark plot was
generated. Finally, an independent dataset containing 23
children treated with the same immunosuppressive regimen
was used for external validation using a VPC. The VPCs
were prediction corrected and stratified for the covariates
included in the final model.
To evaluate the effect of the significant covariates,
simulations were performed using the final population
pharmacokinetic model with varying parameters for the
covariate. For each covariate, concentration–time profiles
were simulated for 1000 patients. All other parameters
were fixed to the median. To develop the dosing guidelines
for the starting dose of tacrolimus, simulations were also
performed using a simulation model, which only included
the covariates that significantly influence the starting dose.
For each combination of these covariates, concentration–
time profiles were simulated for 1000 patients, and a new
starting dose was calculated to reach a target level of
12.5 ng/mL.
Statistical analyses other than those mentioned above,
were performed using SPSS Version 23 (SPSS Inc.,
Chicago, IL, USA). Data on patients’ baseline character-
istics were presented as median and range for continuous
variables.
3 Results
A total of 46 children were included in the model building
group. Patient characteristics are presented in Table 1.
From these patients, 722 blood samples were collected and
analyzed for tacrolimus concentrations (range 2–109 ng/
mL). Each patient had at least one pharmacokinetic profile
over 4 h approximately 2 weeks (range 8–42 days) post-
transplantation. The median number of tacrolimus con-
centrations per patient was 16 (range 9–23). None of the
samples were below the lower limit of quantification. There
was no deviation from the Hardy–Weinberg equilibrium.
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Table 1 Patient characteristics the first 6 weeks after transplantation
Characteristics Model building group (n = 46) Model validation group (n = 23)
Recipient sex, n (%)
Male 26 (56.5) 14 (61.0)
Age of recipient (years) 9.1 (2.4–17.9) 8.2 (1.6–17.1)
Ethnicity, n (%)
Caucasian 34 (73.9) 18 (78.3)
Asian 2 (4.3) 0 (0)
Black 6 (13.0) 1 (4.3)
Other 4 (8.7) 4 (17.4)
Bodyweight (kg)a 28.4 (11.6–83.7) 21.0 (10.4–83.0)
Height (cm)a 128.5 (83.5–186) 120.0 (73.0–176.0)
Laboratory measurementsa
Hematocrit (L/L) 0.29 (0.16–0.43) 0.30 (0.20–0.43)
Creatinine (lmol/L) 72 (12–1454) 65 (12–1148)
eGFR (mL/min/1.73 m2) 69 (3–262) 71 (4–274)
ASAT (U/L) 29 (8–217) Unknown
Albumin (g/L) 33 (11–52) Unknown
Genotype, n (%)
CYP3A4
*1/*1 10 (21.7) 0 (0)
*1/*1G 4 (8.7) 0 (0)
*1G/*1G 2 (4.3) 0 (0)
Unknown 30 (65.2) 23 (100)
CYP3A5
*1/*1 2 (4.3) 0 (0)
*1/*3 5 (10.9) 1 (4.4)
*3/*3 18 (39.1) 9 (39.1)
*3/*7 2 (4.3) 0 (0)
Unknown 19 (41.3) 13 (56.5)
Primary diagnosis, n (%)
CAKUT 23 (50.0) 11 (47.8)
Glomerular kidney disease 13 (28.3) 3 (13.0)
Cystic kidney disease/Nephronophthisis 5 (10.8) 4 (17.4)
Other/unknown 5 (10.8) 5 (21.7)
Number of kidney transplantations, n (%)
First 43 (93.5) 22 (96)
Second 3 (6.5) 1 (4.0)
RRT prior to kidney transplantation, n (%)
Hemodialysis 10 (21.7) 10 (43.5)
Peritoneal dialysis 16 (34.8) 3 (13.0)
Pre-emptive 20 (43.5) 10 (43.5)
Donor type, n (%)
Living 36 (78.3) 19 (82.6)
Deceased 10 (21.7) 4 (17.4)
Mismatch, n (%)
0 3 (6.5) Unknown
1 8 (17.4) Unknown
2 12 (26.1) Unknown
3 23 (50.0) Unknown
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3.1 Base Model
The data were best described by a two-compartment model.
The residual error was described with a combined additive
and proportional error model. Allometric scaling with fixed
exponents [0.75 (CL/F and Q/F) and 1 (V1/F and V2/F)]
significantly improved the model (p\ 0.001). Estimation
of the exponents did not improve the model and resulted in
values not significantly different than the fixed values.
Including IIV on CL/F, V1/F, V2/F, and ka significantly
improved the model fit. The OFV decreased further after
introduction of IOV on CL/F and V2/F. Parameter esti-
mates of the base model, final model, and simulation model
are presented in Table 2.
3.2 Covariate Analysis
The base two-compartment model with allometric scal-
ing was used as a reference for the covariate analysis.
After graphical analysis, the univariate analysis resulted
in ten significant covariates, as shown in Table 3. After
backward elimination, only CYP3A5 genotype, donor,
hematocrit, and eGFR were found to correlate signifi-
cantly with CL/F, and remained in the final model. The
following equation described the final model for esti-
mation of tacrolimus CL/F (L/h) in the first 6 weeks
post-transplant:




 1:0; if CYP3A53=3 or unknownð Þ½
or 2:0; if CYP3A51=3 or CYP3A51=1ð Þ






; if hematocrit\; 0:3
" #
:
3.3 Evaluation of the Final Model
All estimates were within the limits, given the criteria as
defined under Sect. 2, except for shrinkage on V2, which
was 27%. Goodness-of-fit plots of the final model showed
the population predictions and individual predictions were
evenly distributed around the line of unity, and the con-
ditional weighted residuals were normally distributed
(Fig. 1).
A bootstrap analysis with 500 bootstrap replicates was
performed to obtain 95% confidence intervals for all
pharmacokinetic parameters. Owing to minimization and
boundary errors, the bootstrap results were recomputed
without filtering these samples. Results of the bootstrap
are shown in Table 2. Visual predictive checks showed
that the median and the variability fell within the
Table 1 continued
Characteristics Model building group (n = 46) Model validation group (n = 23)
Tacrolimus initial daily dose (mg)a 0.29 (0.23–0.39) 0.31 (0.24–0.54)
First available tacrolimus C0 (ng/mL) 8.7 (2.0–51.4) 8.8 (1.7–29.6)
Route of administration, n (%)
Suspension 13 (28.3) Unknown
Capsule 45 (97.8) Unknown
Co-medication
Calcium channel blockers, n (%)
Amlodipine 15 (32.6) 6 (24.0)
Nifedipine 13 (28.3) 0 (0)
Antibiotics, n (%)
Erythromycin 1 (2.2) 0 (0)
Antimycotics, n (%)
Fluconazole 2 (4.3) Unknown
Voriconazole 1 (2.2) 0 (0)
Glucocorticoids (prednisolone equivalents) dose/day (mg/kg) 0.8 (0.1–17.8) Unknown
ASAT aspartate aminotransferase, C0 pre-dose concentration, CAKUT congenital anomalies of the kidney and the urinary tract, CYP cytochrome
P450, eGFR estimated glomerular filtration rate, RRT renal replacement therapy
a Presented as median and range for continuous variables
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corresponding simulations (Fig. 2a). This demonstrates
the good predictive performance of the final model in the
internal validation. Evaluation of the predictive perfor-
mance by NPDE analysis showed adequate predictive
ability, with distribution of the NPDEs not significantly
deviating from a normal distribution and the majority of
the values were between -2 and 2. Evaluation of the
individual’s influence on a change in OFV by the shark
plot showed 70% of the included children had a decrease
in OFV with the final model vs. the base model. In the
external validation, the median and variability were
adequately described, confirming the validation of the
model (Fig. 2b). There was an insufficient number of
CYP3A5 expressers in this validation cohort to validate
the algorithm for this subgroup.
3.4 Simulations
Based on the final model, CYP3A5 expressers had a two
times higher CL/F. An increase in eGFR from 30 to
90 mL/min resulted in 19% higher CL/F, whereas a
decrease in hematocrit levels from 0.3 to 0.25 L/L corre-
sponded with a 20% higher tacrolimus CL/F. Deceased
donor was associated with a 35% higher tacrolimus CL/
F than living donor. The effects of CYP3A5 genotype,
hematocrit, eGFR, donor, and bodyweight on CL/F are
Table 2 Parameter estimates of the base model, final model, and bootstrap analysis
Parameter Base model Final model Simulation model Bootstrap of the final model
Estimate 95% CI
OFV -411.7 -450.7 -429.4
tlag (h) 0.42 0.37 0.43 0.40 0.30–0.45
ka (L/h) 0.52 0.56 0.43 0.58 0.40–1.25
CL/F (L/h) 48.0 50.5 54.9 54.0 43.5–68.1
V1/F (L) 161 206 119 211 122–363
Q/F (L/h) 147 114 147 116 82–187
V2/F (L) 1950 1520 1900 1544 1052–2140
Covariate effect on CL
CYP3A5*3/*3 1.04 1.00 1.02 0.85–1.21
CYP3A5*1/*1 or *1/*3 1.98 1.82 1.91 1.56–2.43
eGFR (mL/min/1.73 m2) 0.19 0.18 0.04–0.32
Donor living 0.74 0.74 0.70 0.55–0.86
Hematocrit\ 0.3 (L/L) -0.44 -0.42 -0.87 to 0.24
IIV (%)
ka 116 188 119 195 139–256
CL/F 42 25 30 24 17–34
V1/F 115 69 115 82 20–122
V2/F 62 62 89 59 31–87
IOV (%)
CL/F 19 18 19 18 11–23
V2/F 32 35 26 35 22–49
Residual variability
Additional
Immunoassay 0.83 1.01 0.81 0.88 0.01–2.56
LC–MS/MS 0.71 0.28 0.73 0.70 0.01–1.26
Proportional
Immunoassay 0.13 0.13 0.13 0.11 0.001–0.29
LC–MS/MS 0.20 0.21 0.21 0.20 0.15–0.24
CI confidence interval, CL clearance, CYP cytochrome P450, eGFR estimated glomerular filtration rate, F bioavailability of oral tacrolimus, IIV
inter-individual variability, IOV inter-occasion variability, Ka absorption rate constant, LC–MS/MS liquid chromatography-mass spectrometry,
OFV objective function value, Q inter-compartmental clearance of tacrolimus, tlag lag time, V1 central compartment for tacrolimus, V2 peripheral
compartment for tacrolimus
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a b
c d
Fig. 1 Goodness-of-fit plots of
the final model. a Observed
concentration (DV) plotted
against predicted concentration
(PRED). b DV plotted against
individual predicted
concentration (IPRED). c The
correlation of conditional
weighted residuals (CWRES)
with the time after the
tacrolimus dose. d The
correlation of CWRES with
PRED. The line represents the
line of identity. OBS observed
concentration
Table 3 Covariate effects in
the univariate analysis
compared with the base model
Covariate DOFV Covariate effect Included after backward elimination
Covariates on CL/F
Ethnicity 5.3 0.84, 0.95, and 1.15a No
CYP3A5 4.3 0.99 and 1.88b Yes
Donor 6.6 0.73c Yes
Hematocrit\ 0.3 (L/L) 4.6 -0.41 Yes
eGFR (mL/min/1.73 m2) 8.4 0.154 Yes
Age[7 (years)d 3.9 -0.32 No
Covariates on ka
Ethnicity 4.1 1.06, 0.19, and 1.01a No
Hematocrit (L/L) 7.4 2.91 No
Mismatchese 4.7 2.3 No
Covariates on V2
CYP3A4 5.0 1.36, 1.99, and 0.49f No
CYP cytochrome P450, CL/F apparent oral clearance, eGFR estimated glomerular filtration, ka absorption
rate constant, OFV objective function value, V2 peripheral compartment for tacrolimus
a Caucasian, Asian, and Black ethnicity, respectively, compared with subjects from other ethnicities
b CYP3A5 non-expresser and expresser, respectively, compared with unknown genotype
c Living donor compared with a deceased donor
d Age[7 years was chosen after visual inspection of the data. Age as a continuous variable was not a
significant covariate
e No mismatches compared with one or more mismatches
f CYP3A4*1/*1, CYP3A4*1/*1G, and CYP3A4*1G/*1G, respectively, compared with unknown genotype







































visual predictive check (VPC)
showing how well the average
trend of the observations (solid
line) and how well the
variability of the observed data
(two dashed lines) fall within
the model simulated average
trend (red shaded area) and the
model-simulated variability
(blue shaded areas) represented
as a 95% confidence interval
(CI). The average and the
variability of the observed data
both fall within the
corresponding simulations.
a Internal VPC of the final
model. b External VPC of the
final model
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shown in Fig. 3. In total, these covariates explained 41% of
the variability in CL/F.
3.5 Dosing Guidelines
The model was used to design a dosing algorithm for the
starting dose of tacrolimus after pediatric kidney trans-
plantation. The last measured eGFR and hematocrit before
transplantation did not significantly influence the CL/F and
because these parameters change tremendously post-
transplantation, were not incorporated in the algorithm for
the starting dose. The following equation described the




¼ 54:9  weight
70
 0:75
 1:8; if CYP3A51=3 or CYP3A51=1ð Þ
 0:74; if living donorð Þ:
The required dose can be calculated using the






Fig. 3 Simulated plasma profiles of tacrolimus at first steady state
after transplantation. a Simulated plasma profiles of tacrolimus for
cytochrome P450 (CYP) 3A5 non-expressers (CYP3A5*3/*3) and
CYP3A5 expressers (CYP3A5*1/*1 or CYP3A5*1/*3). b Simulated
plasma profiles of tacrolimus for patients receiving a kidney from a
living or deceased donor. c Simulated plasma profiles of tacrolimus
for patients with a bodyweight of 15, 30, 55, or 80 kg. d Simulated
plasma profiles of tacrolimus for patients with plasma hematocrit (Ht)
levels of 0.2, 0.25, and 0.3 L/L. e Simulated plasma profiles of
tacrolimus for patients with an estimated glomerular filtration rate
(eGFR) of 10, 50, or 90 mL/min. conc concentration
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calculate this, AUC0–12h were determined for all the
available pharmacokinetic time profiles. A C0 of 10 ng/
mL corresponded with an AUC0–12h of approximately
177 ng h/mL, 12.5 ng/mL with 209 ng h/mL, 15 ng/mL
with 241 ng h/mL, 17.5 ng/mL with 274 ng h/mL and
20 ng/mL with 306 ng h/mL. Based on the formula:
dose = AUC * CL/F, it leads to the following formula
for a target C0 of 12.5 ng/mL based on a twice-daily
dose:
Dose mgð Þ ¼ 209 ng h=mL  54:9  weight
70
 0:75
 1:8; if CYP3A51=3 or CYP3A51=1ð Þ
 0:74; if living donorð Þ=1000:
This formula can be used when dose adjustments are
based on AUC; however, most hospitals base dose
adjustments on C0. Therefore, dosing guidelines were
developed using the above formula, which was fine tuned
by simulating a 1000 doses in different patients. Table 4
shows the dosing guideline including the simulated median
C0 with the interquartile range at steady state. Dosing
guidelines range from 0.27 mg/kg/day for a CYP3A5 non-
expresser weighing 80 kg receiving a kidney from a living
donor, to 1.33 mg/kg/day for a CYP3A5 expresser
weighing 10 kg and receiving a kidney from a deceased
donor.
4 Discussion
This is the second population pharmacokinetic study of
tacrolimus in pediatric renal transplant recipients covering
the first 6 weeks after transplantation. Our results showed
that a two-compartment model with first-order absorption,
lag time, allometric scaling, IIV on CL, V1, V2, and ka, and
IOV on CL and V2 was optimal for data modeling. Besides
bodyweight, we also demonstrated that CYP3A5 genotype,
hematocrit, eGFR, and donor type all significantly influ-
ence tacrolimus CL. Together these covariates explained
41% of the variability in tacrolimus CL. Calculation of
tacrolimus dosing guidelines for the initial dose after
transplantation showed a factor four difference in daily
dose, ranging from 0.27 to 1.33 mg/kg. This is vastly dif-
ferent from the 0.3 mg/kg/day currently used in clinical
practice [40]. At first steady state, only 26.1% of patients
were within the tacrolimus target C0 range, 67.4% had
subtherapeutic tacrolimus concentrations, and 6.5% had
supratherapeutic concentrations. After a median of
9.8 days (range 1.7–23.8 days), patients were within the
tacrolimus target C0 range.
Genetic polymorphisms in CYP3A5 partly explain the
IIV in tacrolimus pharmacokinetics. In this study, 25.9% of
the included children of whom the genotype was known
were CYP3A5 expressers. In agreement with previously
published data, we report a significantly lower CL/F in
Table 4 Dosing guidelines for
the starting dose of tacrolimus
with a target pre-dose
concentration (C0) of 10–15 ng/
mL
Pharmacogenetics
CYP3A5 expresser CYP3A5 non-expresser
Weight (kg) Donor Dose (mg/kg/day) C0 (ng/mL) Dose (mg/kg/day) C0 (ng/mL)
10 Living 0.89 12.5 (8) 0.44 12.4 (7)
Deceased 1.33 12.3 (8) 0.61 12.2 (7)
20 Living 0.76 12.6 (8) 0.37 12.5 (8)
Deceased 1.06 12.5 (8) 0.53 12.6 (7)
30 Living 0.63 12.5 (8) 0.33 12.5 (7)
Deceased 1.00 12.4 (9) 0.46 12.4 (7)
40 Living 0.61 12.6 (8) 0.31 12.4 (7)
Deceased 0.91 12.5 (9) 0.44 12.6 (7)
50 Living 0.60 12.5 (7) 0.30 12.4 (7)
Deceased 0.82 12.5 (9) 0.42 12.5 (7)
60 Living 0.55 12.5 (8) 0.30 12.5 (8)
Deceased 0.80 12.5 (8) 0.40 12.5 (7)
70 Living 0.53 12.5 (8) 0.30 12.5 (8)
Deceased 0.78 12.5 (8) 0.38 12.5 (7)
80 Living 0.52 12.6 (8) 0.27 12.4 (7)
Deceased 0.78 12.5 (8) 0.38 12.5 (8)
Dosing guidelines for the starting dose of tacrolimus with tacrolimus median C0 at first steady state with
interquartile range as a result of 1000 simulations per patient
CYP cytochrome P450
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children having the CYP3A5*3/*3 genotype compared with
children carrying at least one CYP3A5*1 allele. Given the
wide availability of TDM, genetic testing is most useful
prior to initiation of tacrolimus to more rapidly reach the
target concentration [41]. In adult kidney transplant
recipients, two randomized controlled trials concluded that
optimization of the initial tacrolimus dose using CYP3A5
genetic testing does not improve clinical outcomes when
TDM is performed [26, 42]. As the pharmacokinetics of
tacrolimus differs between children and adults, these
findings cannot be extrapolated. Moreover, our model is
more sophisticated than dosing based on the CYP3A5
genotype only. Therefore, the question remains if geno-
typing in pediatric transplant recipients prior to the start of
tacrolimus therapy adds to adequate dosing of tacrolimus
and improvement of clinical outcomes.
Children with a lower bodyweight had a higher weight-
normalized tacrolimus dose requirement than children with
a higher bodyweight. This is in line with previous findings
[10, 11, 20, 30]. Allometric scaling significantly improved
the model, substantiating findings from previous published
pediatric models [10, 20]. It has been previously reported
that younger children have significantly higher weight-
normalized dose requirements than older recipients, sug-
gesting the dose should be based on age rather than
bodyweight [12, 13]. Incorporation of age in our model did
not improve it further. This is in line with previously
developed pharmacokinetic models in this population
[10, 20, 30].
Contrary to what we expected, kidneys from a deceased
donor had a higher tacrolimus CL than kidneys from a
living donor. This finding was confirmed in the external
validation of the model. A literature search was performed
and showed no previous reports substantiating this obser-
vation. Dialysis prior to kidney transplantation or pre-
emptive kidney transplantation was not significantly asso-
ciated with tacrolimus CL, and neither was the number of
human leukocyte antigen mismatches. As tacrolimus
undergoes hepatic metabolism, higher tacrolimus CL in
kidneys from a deceased donor seems highly unlikely. All
patients received the same immunosuppressive protocol,
regardless of the donor status. Only if there was a slow
graft function, was the start of tacrolimus treatment post-
poned and patients continued treatment with glucocorti-
coids. This occurred in four patients, but none of them
experienced delayed graft function in sensu stricto (i.e., the
need for dialysis in the first week after transplantation).
However, no correlation between slow graft function and
tacrolimus CL was found in these patients. Furthermore,
glucocorticoid use was tested as a covariate and did not
significantly influence tacrolimus CL. Higher tacrolimus
CL in kidneys from a deceased donor is probably caused by
other unknown parameters that could not be tested as
covariates and therefore cannot be corrected for. One of
these parameters could be the interaction between donor
and age. Recipients of a deceased donor kidney tended to
be younger than recipients of a living donor kidney trans-
plant, although this was not statistically significant.
Another explanation could be other non-investigated
parameters such as serum albumin, anemia, and metabolic
acidosis. Recipients of deceased donors are usually more
catabolic and might therefore have a higher free fraction of
tacrolimus. However, this is not supported by our data
showing the difference in CL between living and deceased
donors does not decrease during the first 6 weeks post-
transplantation.
Approximately 70–80% of tacrolimus is distributed in
erythrocytes [43]. This indicates that low hematocrit con-
centrations will reduce the whole-blood concentrations of
tacrolimus. In our cohort, children with a hematocrit
level\0.30 had an increased CL/F and thus required a
higher tacrolimus dose. This is in line with previous find-
ings in pediatric kidney recipients [10, 20]. More than 98%
of tacrolimus in the plasma is bound to plasma proteins,
and despite measuring the tacrolimus concentration in
whole blood, it is actually the unbound concentration that
is pharmacologically active [44]. Hematocrit levels do not
seem to influence the unbound fraction of tacrolimus in
plasma [45]. Low albumin concentrations will increase the
tacrolimus unbound fraction. Unfortunately, there were not
enough albumin measurements available to determine if
there was a relationship between albumin and tacrolimus
CL/F. A recently published study reported the validation of
an assay specifically developed for measurement of
unbound tacrolimus concentrations [46].
In our cohort, children with higher eGFR had higher
tacrolimus CL/F. As an increase in eGFR from 30 to 90 mL/
min resulted in only 19% higher CL/F, eGFR-based dosage
adjustment of tacrolimus seems unnecessary. Tacrolimus
undergoes almost no renal elimination; therefore, the
explanation for the observed association between tacrolimus
CL and eGFR remains unclear. To our knowledge, this is the
first pediatric model to include eGFR. Serum creatinine was
tested in onemodel, but was not significantly correlated with
tacrolimus CL [29]. In adults, some studies have reported no
significant correlation between serum creatinine and tacro-
limus CL [47–49], whereas others did find an effect [50, 51].
Recent data showed that the CYP3A5*1 genotype is associ-
atedwith a greater extent of renal tacrolimusmetabolism and
a lower apparent urinary tacrolimus CL as compared with
subjects expressing CYP3A5*3/*3. This is highly indicative
of intra-renal CYP3A5-dependent tacrolimus metabolism
and could possibly explain the influence of eGFR on tacro-
limus CL/F [52].
There were no patients expressing CYP3A4*22, and
therefore we could not confirm the reported relationship
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between CYP3A4*22 and tacrolimus CL [22]. An associ-
ation between the glucocorticoid dose and tacrolimus CL
has been reported [53, 54]. We could not substantiate this
finding, probably because all children were treated with a
glucocorticoid-minimization regimen and prednisolone
was only prescribed the first 5 days in a relatively low
dose.
The main strength of this study was the extensive
evaluation of the final model; bootstrap analyses, VPCs,
and an NPDE were performed, and the model was also
externally validated. Another strength of the study is the
large amount of blood samples per patient, including
abbreviated tacrolimus pharmacokinetic curves. An
extensive literature search was performed and all covari-
ates known to influence the CL of tacrolimus, were tested.
The population pharmacokinetic model was developed in
patients treated according to the same immunosuppressive
protocol. Other studies included children with different
regimens, for example, with azathioprine instead of
mycophenolic acid or glucocorticoids in different doses,
making it difficult to determine the effect of tacrolimus.
The final strength of the study is that dosing guidelines for
the starting dose of tacrolimus after renal transplantation
were developed. These dosing guidelines will be prospec-
tively tested.
The main limitation of this study is that it is a retro-
spective analysis and therefore we had to rely on data
available in the medical records. Because of this limitation
we did not include a patient expressing CYP3A4*22, nor
did we have enough CYP3A5 expressers in the validation
cohort. Another limitation is that during the study period
the tacrolimus analysis changed from the immunoassay to
an LC–MS/MS. However, this difference was built into the
residual error model. Furthermore, the relatively large
proportion of Caucasian patients in our center is a limita-
tion. Finally, the developed population pharmacokinetic
model is only suitable for children aged between 2 and
18 years receiving immediate-release formulations of
tacrolimus, as the once-daily preparation was not tested.
5 Conclusions
The population pharmacokinetics of tacrolimus during the
first 6 weeks after renal transplantation can be adequately
described using the model presented in this article. Higher
bodyweight, lower eGFR, and higher hematocrit levels
resulted in lower tacrolimus CL. CYP3A5 expressers and
recipients who received a kidney from a deceased donor
had higher tacrolimus CL. The tacrolimus weight-normal-
ized starting dose should be higher in patients with lower
bodyweight, in those who are CYP3A5 expressers, and in
patients receiving a kidney from a deceased donor. By
combining these parameters, an individualized tacrolimus
dosing regimen has been developed that adequately pre-
dicts the target C0 and hopefully will improve patient
outcome.
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